Zobrazeno 1 - 10
of 211
pro vyhledávání: '"Soule, H"'
Autor:
Xie, W., Ravi, P., Buyse, M., Halabi, S., Kantoff, P., Sartor, O., Soule, H., Clarke, N., Dignam, J., James, N., Fizazi, K., Gillessen, S., Mottet, N., Murphy, L., Parulekar, W., Sandler, H., Tombal, B., Williams, S., Sweeney, C.J.
Publikováno v:
In Annals of Oncology March 2024 35(3):285-292
Publikováno v:
In Clinical Microbiology and Infection July 2019 25(7):851-856
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::954a4705c86069ada984214c24c0216d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220070
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220070
The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained. The authors would like to apologise for any inconvenience cau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::880f4decc153a541b10851745554257e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3219271
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3219271
Publikováno v:
In Réanimation July 2009 18(5):407-412
At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::111bccfde2148d4e3b07eb07bf1c8c22
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104607
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104607
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xie, W, Regan, M, Buyse, M, Halabi, S, Kantoff, P, Sartor, O, Soule, H, Clarke, N, Collette, L, Dignam, J, Fizazi, K, Paruleker, W, Sandler, H, Sydes, M, Tombal, B, Williams, S, Sweeney, C, Andren, O, Armstrong, J, Berry, D, Bolla, M, Chin, J, Chowdhury, S, Cooperberg, M, Denham, J, Di Stasi, S, Eisenberger, M, Freidlin, B, Gillessen, S, Gleave, M, Habibian, M, James, N, Jarow, J, Keating, N, Keloff, G, Klotz, L, Lukka, H, Mason, M, Miyahira, A, Mottet, N, Nakabayashi, M, Parulekar, W, Scardino, P, Scher, H, Simon, R, Simons, J, Small, E, Tangen, C, Thompson, I, Widmark, A, Wiegel, T, Wirth, M, Yeoh, E, Zapatero, A
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 201
Autor:
Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bossi, A, Bristow, R, Carver, B, Castellano, D, Chung, BH, Clarke, N, Daugaard, G, Davis, ID, de Bono, J, Borges dos Reis, R, Drake, CG, Eeles, R, Efstathiou, E, Evans, CP, Fanti, S, Feng, F, Fizazi, K, Frydenberg, M, Gleave, M, Halabi, S, Heidenreich, A, Higano, CS, James, N, Kantoff, P, Kellokumpu-Lehtinen, PL, Khauli, RB, Kramer, G, Logothetis, C, Maluf, F, Morgans, AK, Morris, MJ, Mottet, N, Murthy, V, Oh, W, Ost, P, Padhani, AR, Parker, C, Pritchard, CC, Roach, M, Rubin, MA, Ryan, C, Saad, F, Sartor, O, Scher, H, Sella, A, Shore, N, Smith, M, Soule, H, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, MR, Tannock, I, Tombal, B, Valdagni, R, Wiegel, T, Omlin, A
Publikováno v:
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; et al.(2018). Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]. European Urology, 73(2), 178-211. doi: 10.1016/j.eururo.2017.06.002. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/35r8p27w
© 2017 European Association of Urology Background In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::f32df29474e6cca620916a1041804d21
http://www.escholarship.org/uc/item/35r8p27w
http://www.escholarship.org/uc/item/35r8p27w
Autor:
Seyednasrollah, F., Köstler, D.C., Wang, T., Piccolo, S.R., Vega, R., Greiner, R., Fuchs, C., Gofer, E., Kumar, L., Wolfinger, R.D., Kanigel-Winner, K., Bare, C., Neto, E.C., Yu, T., Shen, L., Abdallah, K., Norman, T., Stolovitzky, G., Soule, H., Sweeney, C.J., Ryan, C.J., Scher, H.I., Sartor, O, Elo, L.L., Zhou, F.L., Guinney, J., Costello, J.C., Prostate Cancer Challenge DREAM Community (Kondofersky, I., Krautenbacher, N., Laimighofer, M., Scherb, H., Söllner, J.F., Kurz, C.F.)
Publikováno v:
JCO Clinical Cancer Informatics
JCO Clin. Can. Inform. 1, 1-15 (2017)
Prostate Cancer DREAM Challenge Community 2017, ' A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer ', JCO clinical cancer informatics, vol. 2017, no. 1, pp. 1-15 . https://doi.org/10.1200/CCI.17.00018
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
JCO Clin. Can. Inform. 1, 1-15 (2017)
Prostate Cancer DREAM Challenge Community 2017, ' A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer ', JCO clinical cancer informatics, vol. 2017, no. 1, pp. 1-15 . https://doi.org/10.1200/CCI.17.00018
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Purpose Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d3f55e5a5398b4392a9ea014add66e
https://hdl.handle.net/1822/59520
https://hdl.handle.net/1822/59520